GlassScriptPhysician profile
Shephali Patel
NPI 1154870186
$5,195.92
in general payments reported to CMS, 2019-2025
35 companies · $1,405 in 2025
The $1,405 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,519 · 2022: $1,050 · 2023: $264 · 2024: $957 · 2025: $1,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,556 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,556.37 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,194.56 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $519.53 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $370.78 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $351.78 | 2021-2025 | Winrevair, Verquvo |
| Pfizer INC. | $309.16 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $298.18 | 2021-2025 | Farxiga, Wainua, Lokelma |
| Actelion Pharmaceuticals US, INC. | $291.07 | 2024-2025 | Opsumit, Uptravi |
| Esperion Therapeutics, INC. | $201.12 | 2021-2023 | Nexletol |
| Amgen INC. | $151.62 | 2021-2025 | Repatha, Repatha |
| Regeneron Healthcare Solutions, INC. | $148.69 | 2024-2025 | Evkeeza |
| Impulse Dynamics (USA) INC. | $137.01 | 2021 | |
| Cvrx, INC. | $129.16 | 2022-2025 | Barostim Neo System |
| Biosense Webster, INC. | $124.86 | 2022 | |
| Boston Scientific Corporation | $122.98 | 2021-2024 | Bodyguardian, Lux-Dx Insertable Cardiac Monitor |
| E.R. Squibb & Sons, L.L.C. | $117.31 | 2024-2025 | Eliquis, Camzyos |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $103.66 | 2021-2023 | Lifevest |
| Bridgebio Pharma, INC. | $84.92 | 2025 | Attruby |
| Medtronic, INC. | $73.90 | 2021-2022 | |
| Ionis Pharmaceuticals, INC. | $48.70 | 2025 | Tryngolza |
| Amarin Pharma, INC. | $35.49 | 2021-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $33.82 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $32.25 | 2021-2022 | |
| United Therapeutics Corporation | $32.06 | 2025 | Tyvaso |
| Imperative Care, INC | $30.93 | 2024 | Symphony Catheter |
| Scpharmaceuticals INC. | $30.44 | 2025 | |
| Abbott Laboratories | $29.44 | 2022 | |
| Abiomed | $28.50 | 2024 | Impella |
| Kiniksa Pharmaceuticals, LTD. | $27.20 | 2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $25.31 | 2025 | Amvuttra |
| Inspiremd LTD | $24.41 | 2025 | Cguard Prime Carotid Stent System |
| Jazz Pharmaceuticals INC. | $21.48 | 2023 | |
| Mallinckrodt Hospital Products INC. | $19.54 | 2023 | Acthar |
| Baxter Healthcare | $15.50 | 2022 | |
| Innovation Technologies INC | $15.42 | 2025 | Irrisept |
| Lexicon Pharmaceuticals, INC. | $15.14 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shephali Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.